Menopausal Hormone Therapy and Breast Cancer Trends in Canada

Rapid decline and subsequent rise in Canadian breast cancer incidence after 2002 publication of WHI results provide insights about the association between HT use and breast cancer risk.

After results of the Women's Health Initiative (WHI) trial of estrogen-progestin hormone therapy (HT) were published in 2002 (JW Womens Health Aug 7 2002), HT use declined precipitously among U.S. women; moreover, the nationwide incidence of invasive breast cancer fell by almost 12% between 2001 and 2004 (JW Oncol Hematol May 14 2007). Among older Canadian women (age range, 50–69), use of combination HT declined by 9.9% annually from 2000 through 2006. Now, Canadian investigators have used age-standardized national incidence rates of invasive breast cancer from 1996 through 2006 to assess trends in breast cancer incidence before and after 2002.

Among younger Canadian women (age range, 40–49), incidence of invasive breast cancer remained rela…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Menopausal Hormone Therapy and Breast Cancer Trends in Canada

Topics

Reviewing Author